Jazz Pharmaceuticals plc 8-K

What Happened
Jazz Pharmaceuticals plc (JAZZ) filed an 8-K reporting that Class III director Anne O’Riordan informed the Board on May 25, 2026 that she will not stand for re‑election at the company’s 2026 annual meeting of shareholders. The company said this decision was not the result of any dispute or disagreement with Jazz or its Board. The filing was signed by Neena Patil, Executive Vice President and Chief Legal Officer, on May 29, 2026.

Key Details

• Anne O’Riordan is a Class III director; her term expires at Jazz’s 2026 annual meeting.
• Notification to the Board received on May 25, 2026.
• Company statement: decision was not due to any dispute or disagreement with the Company or Board.
• Board will continue to evaluate board composition and facilitate orderly board succession.

Why It Matters
A director choosing not to stand for re‑election is a governance and succession event. It can affect the board’s composition and the company’s upcoming proxy/nomination materials, but the filing does not indicate any dispute or operational issues. Investors monitoring Jazz’s corporate governance should watch for announcements about director nominees and any changes to the board slate ahead of the 2026 annual meeting.